Loading
Since 1973 the not-for-profit group that designs and runs independent blood cancer trials across Australia and New Zealand, with more than 600 clinicians, scientists and support staff.
The ALLG states that it is the only not-for-profit collaborative clinical research group in Australia and New Zealand dedicated to designing and conducting independent clinical trials for blood cancers, providing the infrastructure and governance for more than 600 clinicians, scientists and support staff to run multi-site trials in leukaemia, lymphoma, myeloma and related diseases. Its purpose has been 'Better treatments... Better lives' since 1973. It is registered as an income tax exempt charity and works from Richmond, Melbourne.
Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML.
Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.
Shares Cancer Australia, Peter MacCallum Cancer Centre and the tag cooperative-group.
Shares Cancer Australia, Peter MacCallum Cancer Centre and the tag cooperative-group.
Shares Cancer Australia and the tag cooperative-group.
Shares Cancer Australia, Peter MacCallum Cancer Centre and the tag cooperative-group.
Shares Cancer Australia, Peter MacCallum Cancer Centre and the tag cooperative-group.
Shares Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma and the tag cooperative-group.
Shares Acute myeloid leukaemia, Multiple myeloma and the tag cooperative-group.
Shares Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma and the tag cooperative-group.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/